Benzinga

Benzinga

Benzinga

viernes, agosto 21

AbbVie Inc

ABBVNYSE
Trade with Public
Trade with Public
$261.83
-4.14-1.56%
al cierre: Aug 20, 5:00 PM EST
$261.19
-0.64-0.24%
After hour: 5:47 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararOpcionesInforme de acciones

AbbVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbbVie (ABBV).

Price Target Range — 8 Quarters

Analyst Consensus — 23 Analysts

19Buy
4Hold
Consensus RatingOverweight# Analysts23Avg. Consensus PT$260Upside to Avg. PT-0.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 20, 2026Piper SandlerDavid AmsellemPT RaiseOverweight$298→$303
Aug 17, 2026Wells FargoMohit BansalPT RaiseOverweight$295→$300
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $298 to $303.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.
Benzinga Newsdesk

PRO
Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target

Wolfe Research analyst Alexandria Hammond upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.
Benzinga Newsdesk

PRO
BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247

BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $261 to $288.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved